CN101754767A - 移植物抗宿主疾病的治疗 - Google Patents
移植物抗宿主疾病的治疗 Download PDFInfo
- Publication number
- CN101754767A CN101754767A CN200880100116A CN200880100116A CN101754767A CN 101754767 A CN101754767 A CN 101754767A CN 200880100116 A CN200880100116 A CN 200880100116A CN 200880100116 A CN200880100116 A CN 200880100116A CN 101754767 A CN101754767 A CN 101754767A
- Authority
- CN
- China
- Prior art keywords
- cell
- bone marrow
- stem cell
- clone
- same race
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title claims description 46
- 208000024908 graft versus host disease Diseases 0.000 title claims description 45
- 210000000130 stem cell Anatomy 0.000 claims abstract description 134
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 81
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000001154 acute effect Effects 0.000 claims abstract description 11
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 46
- 230000037396 body weight Effects 0.000 claims description 34
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 31
- 208000024891 symptom Diseases 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 28
- 102000003814 Interleukin-10 Human genes 0.000 claims description 19
- 108090000174 Interleukin-10 Proteins 0.000 claims description 19
- 229940076144 interleukin-10 Drugs 0.000 claims description 19
- 102100032912 CD44 antigen Human genes 0.000 claims description 16
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 16
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 16
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 16
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 16
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- 102100024210 CD166 antigen Human genes 0.000 claims description 10
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 9
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 7
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 210000003608 fece Anatomy 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 5
- 108010049003 Fibrinogen Proteins 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 229940012952 fibrinogen Drugs 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 208000016332 liver symptom Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 206010013975 Dyspnoeas Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 210000003141 lower extremity Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000001364 upper extremity Anatomy 0.000 claims description 3
- 102100037241 Endoglin Human genes 0.000 claims 6
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 6
- 230000001413 cellular effect Effects 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 abstract description 31
- 208000024340 acute graft versus host disease Diseases 0.000 abstract description 13
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000000926 separation method Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000012531 culture fluid Substances 0.000 description 7
- 229960003444 immunosuppressant agent Drugs 0.000 description 7
- 230000001861 immunosuppressant effect Effects 0.000 description 7
- 239000003018 immunosuppressive agent Substances 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000829111 Human polyomavirus 1 Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 5
- 229960004866 mycophenolate mofetil Drugs 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- -1 CD31 Proteins 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002052 colonoscopy Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960000724 cidofovir Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000019775 Back disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001232809 Chorista Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000001096 cystic duct Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002151 serous membrane Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94034907P | 2007-05-25 | 2007-05-25 | |
| US60/940,349 | 2007-05-25 | ||
| KR10-2007-0053298 | 2007-05-31 | ||
| KR1020070053298A KR20080105555A (ko) | 2007-05-31 | 2007-05-31 | 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법 |
| PCT/IB2008/003005 WO2009040666A2 (en) | 2007-05-25 | 2008-05-27 | Treatment of graft-versus-host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101754767A true CN101754767A (zh) | 2010-06-23 |
Family
ID=40072607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880100116A Pending CN101754767A (zh) | 2007-05-25 | 2008-05-27 | 移植物抗宿主疾病的治疗 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9439929B2 (enExample) |
| EP (1) | EP2160100B8 (enExample) |
| JP (1) | JP5683264B2 (enExample) |
| KR (1) | KR20080105555A (enExample) |
| CN (1) | CN101754767A (enExample) |
| ES (1) | ES2628362T3 (enExample) |
| WO (1) | WO2009040666A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674818A (zh) * | 2018-09-29 | 2019-04-26 | 南方医科大学南方医院 | hAMSCs在制备治疗急性移植物抗宿主病药物中的用途 |
| CN115361960A (zh) * | 2020-02-19 | 2022-11-18 | 迈索布拉斯特国际有限公司 | 用于治疗慢性移植物抗宿主病的方法 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080105555A (ko) * | 2007-05-31 | 2008-12-04 | 인하대학교 산학협력단 | 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법 |
| US8545888B2 (en) * | 2007-06-14 | 2013-10-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tendon stem cells |
| MX339624B (es) | 2008-08-20 | 2016-06-02 | Anthrogenesis Corp | Composiciones mejoradas de celulas y metodos para preparar las mismas. |
| CA2767970C (en) | 2009-07-13 | 2019-10-08 | Biogencell, Ltd. | Method for using directing cells for specific stem/progenitor cell activation and differentiation |
| KR101694554B1 (ko) * | 2011-08-30 | 2017-01-18 | 가톨릭대학교 산학협력단 | 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물 |
| KR101705378B1 (ko) * | 2011-09-23 | 2017-02-13 | 가톨릭대학교 산학협력단 | 간엽줄기세포 및 ⅰｌ-21 차단제를 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물 |
| US8956870B2 (en) | 2012-01-19 | 2015-02-17 | Biogencell, Ltd. | Method for using directing cells for specific stem/progenitor cell activation and differentiation |
| US20180005156A1 (en) * | 2015-01-20 | 2018-01-04 | Ge Healthcare Bio-Sciences Corp. | Process Simulation in a Cell Processing Facility |
| AU2018234827B2 (en) | 2017-03-15 | 2024-04-04 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
| JP7467358B2 (ja) | 2018-02-20 | 2024-04-15 | ウニヴェルシテ・ドゥ・モントリオール | 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大 |
| KR102096886B1 (ko) * | 2018-06-04 | 2020-04-03 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 이식편대숙주 질환 예방 혹은 치료용 조성물 |
| US20220387504A1 (en) * | 2018-12-17 | 2022-12-08 | Scm Lifescience Co., Ltd. | Pharmaceutical composition comprising clonal stem cells for treating graft-versus-host disease |
| JP2023521157A (ja) * | 2020-04-06 | 2023-05-23 | アールエックスセル インコーポレーテッド | 低免疫原性の細胞ならびにそれらの産生のための方法および組成物 |
| KR102880848B1 (ko) * | 2024-03-11 | 2025-11-04 | 에스씨엠생명과학 주식회사 | 중간엽 줄기세포의 신속 층분리 배양 방법 |
| WO2025192960A1 (ko) * | 2024-03-11 | 2025-09-18 | 에스씨엠생명과학 주식회사 | 중간엽 줄기세포의 신속 층분리 배양 방법 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047163A2 (en) * | 1998-03-18 | 1999-09-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| US20050142119A1 (en) * | 2000-06-05 | 2005-06-30 | Beerelli Seshi | Human mesenchymal progenitor cell |
| US20060286669A1 (en) * | 2005-06-17 | 2006-12-21 | Song Sun U | Isolation of multi-lineage stem cells |
| US20080292601A1 (en) * | 2007-05-25 | 2008-11-27 | Song Sun Uk | Treatment of graft-versus-host disease with il-10 expressing cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
| US5426098A (en) * | 1993-09-02 | 1995-06-20 | Celtrix Pharmaceuticals, Inc. | Increase in hematopoietic progenitor cells in peripheral blood by transforming growth factor beta |
| US5827742A (en) | 1994-09-01 | 1998-10-27 | Beth Israel Deaconess Medical Center, Inc. | Method of selecting pluripotent hematopioetic progenitor cells |
| US6082364A (en) | 1997-12-15 | 2000-07-04 | Musculoskeletal Development Enterprises, Llc | Pluripotential bone marrow cell line and methods of using the same |
| US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| EP2298861B1 (en) * | 2004-03-22 | 2017-09-13 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
-
2007
- 2007-05-31 KR KR1020070053298A patent/KR20080105555A/ko not_active Ceased
-
2008
- 2008-05-27 US US12/127,734 patent/US9439929B2/en active Active
- 2008-05-27 JP JP2010508932A patent/JP5683264B2/ja active Active
- 2008-05-27 ES ES08834068.2T patent/ES2628362T3/es active Active
- 2008-05-27 CN CN200880100116A patent/CN101754767A/zh active Pending
- 2008-05-27 WO PCT/IB2008/003005 patent/WO2009040666A2/en not_active Ceased
- 2008-05-27 US US12/127,743 patent/US20080292601A1/en not_active Abandoned
- 2008-05-27 EP EP08834068.2A patent/EP2160100B8/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047163A2 (en) * | 1998-03-18 | 1999-09-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| US20050142119A1 (en) * | 2000-06-05 | 2005-06-30 | Beerelli Seshi | Human mesenchymal progenitor cell |
| US20060286669A1 (en) * | 2005-06-17 | 2006-12-21 | Song Sun U | Isolation of multi-lineage stem cells |
| US20080292601A1 (en) * | 2007-05-25 | 2008-11-27 | Song Sun Uk | Treatment of graft-versus-host disease with il-10 expressing cells |
Non-Patent Citations (3)
| Title |
|---|
| BRONWYN JONES 等: ""Computed Tomography of Gastrointestinal Inflammation after Bone Marrow Transplantation"", 《AMERICAN JOURNAL OF ROENTGENOLOGY》 * |
| MARK F. PITTENGER等: ""Multilineage Potential of Adult Human Mesenchymal Stem Cells"", 《SCIENCE》 * |
| N FUJII等: ""Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation"", 《BONE MARROW TRANSPLANTATION》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674818A (zh) * | 2018-09-29 | 2019-04-26 | 南方医科大学南方医院 | hAMSCs在制备治疗急性移植物抗宿主病药物中的用途 |
| CN115361960A (zh) * | 2020-02-19 | 2022-11-18 | 迈索布拉斯特国际有限公司 | 用于治疗慢性移植物抗宿主病的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080292600A1 (en) | 2008-11-27 |
| EP2160100B1 (en) | 2017-03-15 |
| EP2160100A2 (en) | 2010-03-10 |
| US20080292601A1 (en) | 2008-11-27 |
| WO2009040666A3 (en) | 2009-12-30 |
| ES2628362T3 (es) | 2017-08-02 |
| EP2160100A4 (en) | 2011-08-31 |
| US20160166614A9 (en) | 2016-06-16 |
| JP5683264B2 (ja) | 2015-03-11 |
| EP2160100B8 (en) | 2017-07-05 |
| JP2010527988A (ja) | 2010-08-19 |
| US9439929B2 (en) | 2016-09-13 |
| KR20080105555A (ko) | 2008-12-04 |
| WO2009040666A2 (en) | 2009-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101754767A (zh) | 移植物抗宿主疾病的治疗 | |
| JP6560381B2 (ja) | 脂肪組織または胎盤組織に由来する接着性細胞および治療におけるその使用 | |
| ES2589311T3 (es) | Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos | |
| KR101578591B1 (ko) | 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| JP5431146B2 (ja) | 免疫学的寛容および調節性前駆細胞 | |
| AU2014344795B2 (en) | Cell culture method | |
| CN104357383A (zh) | 人脂肪间充质干细胞制备方法及其在制备疾病药物的应用 | |
| US20180303879A1 (en) | Methods of treating or preventing rheumatic disease | |
| Comite et al. | Isolation and ex vivo expansion of bone marrow–derived porcine mesenchymal stromal cells: potential for application in an experimental model of solid organ transplantation in large animals | |
| Ding et al. | Mesenchymal stem cell transplantation: a potential therapy for oral lichen planus | |
| KR101766341B1 (ko) | 비만세포 과립을 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 | |
| CN103655614B (zh) | 脂肪组织祖细胞在预防或治疗肝炎中的应用 | |
| TWI656215B (zh) | 自周邊血液製備間質幹細胞群的方法及其用途 | |
| KR20130125569A (ko) | 활막액으로부터 중간엽 줄기세포를 분리하는 방법 | |
| WO2022074624A1 (es) | Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores | |
| CN116970556A (zh) | 自离体的包皮组织取得人类间质干细胞的方法及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: INHA-INDUSTRY PARTNERSHIP INSTITUTE Free format text: FORMER OWNER: HOMOEOPATHY LIMITED COMPANY Effective date: 20140821 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140821 Address after: Inchon Applicant after: Inha Industry Partnership Inst Address before: Inchon Applicant before: Inha Ind Partnership Inst |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100623 |
|
| RJ01 | Rejection of invention patent application after publication |